Page Limit Blunder Blocks Janssen’s Bid To Bar Amgen’s Ustekinumab
US District Court Pulls Up Janssen For Seven Minute Warning To Its Request
Executive Summary
Janssen was pulled up for paperwork chicanery as it looked to obtain an early preliminary injunction against Amgen’s proposed biosimilar to its Stelara (ustekinumab).
You may also be interested in...
Dr Reddy’s Can Still Go It Alone After Penning Orencia Biosimilar Deal
Targeting a dual biologic for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, Coya Therapeutics has joined forces with abatacept biosimilar developer Dr Reddy’s.
Waverley Weighs Its Options With High Costs, Thin Margins
Waverley is evaluating options for its generics as it looks likely to throw its all at the company’s lead product candidate in the hopes of luring a development partner or buyer.
Eagle: ‘No Room, No Reason’ For A Generics Business, As Vasopressin Pulled
In something of a surprise, Eagle Pharmaceuticals has announced its exit from the generic vasopressin market – one year after a hard-fought and hard-won launch.